IN2014CN02850A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02850A
IN2014CN02850A IN2850CHN2014A IN2014CN02850A IN 2014CN02850 A IN2014CN02850 A IN 2014CN02850A IN 2850CHN2014 A IN2850CHN2014 A IN 2850CHN2014A IN 2014CN02850 A IN2014CN02850 A IN 2014CN02850A
Authority
IN
India
Prior art keywords
methylbenzenesulfonamide
indazol
reconstitution
pyrimidinyl
methylamino
Prior art date
Application number
Other languages
English (en)
Inventor
Augustus Campbell Gossett
Helen Richardson
Peter A Williams
Original Assignee
Glaxosmithkline Intellectual Property Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Ltd filed Critical Glaxosmithkline Intellectual Property Ltd
Publication of IN2014CN02850A publication Critical patent/IN2014CN02850A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2850CHN2014 2011-10-31 2012-10-16 IN2014CN02850A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553454P 2011-10-31 2011-10-31
PCT/US2012/060361 WO2013066616A1 (fr) 2011-10-31 2012-10-16 Formulation de pazopanib

Publications (1)

Publication Number Publication Date
IN2014CN02850A true IN2014CN02850A (fr) 2015-07-03

Family

ID=48192602

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2850CHN2014 IN2014CN02850A (fr) 2011-10-31 2012-10-16

Country Status (12)

Country Link
US (3) US9278099B2 (fr)
EP (1) EP2773204A4 (fr)
JP (2) JP6200893B2 (fr)
KR (1) KR101993436B1 (fr)
CN (1) CN104254249B (fr)
AU (1) AU2012332952B2 (fr)
BR (1) BR112014010551A2 (fr)
CA (1) CA2852912A1 (fr)
HK (1) HK1201685A1 (fr)
IN (1) IN2014CN02850A (fr)
RU (1) RU2616500C2 (fr)
WO (1) WO2013066616A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA201502073B (en) * 2014-03-28 2016-03-30 Cipla Ltd Pharmaceutical composition
EP3612184B1 (fr) * 2017-04-17 2024-06-05 Yale University Composés, compositions et méthodes de traitement ou de prévention d'une lésion pulmonaire aiguë
WO2019053500A1 (fr) 2018-04-17 2019-03-21 Alvogen Malta Operations (Row) Ltd Composition pharmaceutique de forme posologique solide contenant du pazopanib et son procédé de préparation
WO2019208540A1 (fr) 2018-04-24 2019-10-31 塩野義製薬株式会社 Formulation solide présentant une excellente stabilité

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH675537A5 (fr) 1988-03-25 1990-10-15 Ciba Geigy Ag
DE58903964D1 (de) * 1988-11-10 1993-05-06 Ciba Geigy Ag Fluessige orale formulierung.
ES2324981T3 (es) * 2000-12-21 2009-08-21 Smithkline Beecham Corporation Pirimidinaminas como moduladores de la angiogenesis.
HRP20020923A2 (en) * 2001-11-23 2003-10-31 Glaxo Group Ltd Pharmaceutical composition
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
CA2631173A1 (fr) 2005-11-29 2007-06-07 Smithkline Beecham Corporation Procede de traitement
JP2009517397A (ja) * 2005-11-29 2009-04-30 スミスクライン ビーチャム コーポレーション 癌の治療方法
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JP2011503105A (ja) * 2007-11-12 2011-01-27 ノバルティス アーゲー バルサルタン含有液体組成物
CL2008000374A1 (es) 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのlfa−1アンタゴニストの送達
WO2010037095A2 (fr) * 2008-09-29 2010-04-01 Nometics Agents et procédés pour le traitement du cancer
US20100291025A1 (en) 2009-04-13 2010-11-18 Auspex Pharmaceuticals, Inc. Indazole inhibitors of tyrosine kinase
EP2298321A1 (fr) * 2009-08-26 2011-03-23 Nordic Pharma Nouvelles compositions pharmaceutiques pour le traitement de maladies intestinales inflammatoires
US8501811B2 (en) * 2010-06-17 2013-08-06 Washington University TASPASE1 inhibitors and their uses

Also Published As

Publication number Publication date
CA2852912A1 (fr) 2013-05-10
RU2014115289A (ru) 2015-12-10
US20160120988A1 (en) 2016-05-05
US20180360971A1 (en) 2018-12-20
WO2013066616A1 (fr) 2013-05-10
EP2773204A1 (fr) 2014-09-10
JP6200893B2 (ja) 2017-09-20
JP6423484B2 (ja) 2018-11-14
HK1201685A1 (en) 2015-09-11
JP2017197542A (ja) 2017-11-02
CN104254249B (zh) 2017-02-15
BR112014010551A2 (pt) 2017-05-02
US10596263B2 (en) 2020-03-24
CN104254249A (zh) 2014-12-31
US20140255505A1 (en) 2014-09-11
JP2014534215A (ja) 2014-12-18
US10080802B2 (en) 2018-09-25
AU2012332952B2 (en) 2016-05-05
EP2773204A4 (fr) 2015-05-27
AU2012332952A1 (en) 2014-05-15
KR20140096082A (ko) 2014-08-04
US9278099B2 (en) 2016-03-08
RU2616500C2 (ru) 2017-04-17
KR101993436B1 (ko) 2019-06-26

Similar Documents

Publication Publication Date Title
PH12016501535A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
BR112012031297A2 (pt) formulações de spray oral e métodos para administração de sildenafil
MX2013001677A (es) Formulaciones estables de linaclotida.
SG10201804817TA (en) Delayed release compositions of linaclotide
RS53898B1 (en) QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS
MD20150050A2 (ro) Soluţii midriatice şi antiinflamatorii stabile fără conservanţi pentru injectare
GEP201706774B (en) Heterocyclyl compounds
MX357043B (es) Inhibidores selectivos de pi3k delta.
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
IL217052A0 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
MX2013007104A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
NZ707160A (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
NZ628072A (en) Crystalline pi3 kinase inhibitors
UA116875C2 (uk) Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
MX2013010046A (es) Administracion parenteral de tapentadol.
IN2014CN02850A (fr)
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
EP4327828A3 (fr) Formes solides de ceftolozane
MX2016001896A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico.
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
TN2012000105A1 (en) Spirolactam derivatives and uses of same
GEP20146182B (en) Delta crystalline form of arginine salt of perindopril, process for its preparation, and pharmaceutical com¬po¬- sitions containing it